Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes

被引:30
作者
Altinova, Alev E. [1 ]
Toruner, Fusun [1 ]
Akturk, Mujde [1 ]
Bukan, Neslihan [2 ]
Yetkin, Ilhan [1 ]
Cakir, Nuri [1 ]
Arslan, Metin [1 ]
机构
[1] Gazi Univ, Fac Med, Dept Endocrinol & Metab, Ankara, Turkey
[2] Gazi Univ, Fac Med, Dept Biochem, Ankara, Turkey
关键词
Osteoprotegerin; type; 2; diabetes; nephropathy; glycemic control; renal function; PLASMA OSTEOPROTEGERIN; INSULIN-RESISTANCE; CALCIFICATION; DISEASE; LIGAND; ASSOCIATION; GLUCOSE; OBESE; RISK; MEN;
D O I
10.3109/00365513.2011.570868
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
100103 [病原生物学]; 100218 [急诊医学];
摘要
We aimed to investigate the relationship between serum osteoprotegerin (OPG) level and glycemic control, lipids, renal function, microalbuminuria, insulin resistance and markers of atherosclerosis including C-reactive protein (CRP), fibrinogen and erythrocyte sedimentation rate (ESR) in patients with type 2 diabetes mellitus (DM). A total of 166 patients (99 women and 67 men) with type 2 DM were recruited in the study. Serum OPG level was higher in poorly controlled diabetic patients (HbA(1c) >= a parts per thousand yen 7%) than in well-controlled diabetic patients (HbA(1c) < 7%) [4.0 (3.6--5.0) and 3.5 (2.9--4.4) pmol/L, p == 0.02]. There was no difference between the patients with and without microalbuminuria with respect to OPG levels (p > 0.05). LogOPG was correlated with age (r == 0.47, p == 0.0001). After adjustment for age, sex and BMI, logOPG correlated positively with fasting blood glucose (FBG) (r == 0.28, p == 0.001), prandial blood glucose (PBG) (r == 0.22, p == 0.009), glycated hemoglobin (HbA(1c)) (r == 0.26, p == 0.002), logHOMA-IR (r == 0.30, p == 0.006), fibrinogen (r == 0.17, p == 0.04), mean albumin excretion rate (MAER) (r == 0.20, p == 0.01) and negatively with creatinine clearance (r == -- 0.20, p == 0.01). Regression analysis revealed that logOPG was independently associated with age (p == 0.0001), HbA(1c) (p == 0.01) and MAER (p == 0.02) (r<SU2</SU == 0.25). In conclusion; we found that serum OPG levels are increased in poorly controlled type 2 DM and associated with age, glycemic control and microalbuminuria.
引用
收藏
页码:340 / 343
页数:4
相关论文
共 25 条
[1]
American Diabetes Association, 2004, Diabetes Care, V27 Suppl 1, pS5, DOI 10.2337/diacare.27.2007.S5
[2]
The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects [J].
Anand, DV ;
Lahiri, A ;
Lim, E ;
Hopkins, D ;
Corder, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (09) :1850-1857
[3]
Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption [J].
Aubin, JE ;
Bonnelye, E .
OSTEOPOROSIS INTERNATIONAL, 2000, 11 (11) :905-913
[4]
Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients [J].
Avignon, A ;
Sultan, A ;
Piot, C ;
Elaerts, S ;
Cristol, JP ;
Dupuy, AM .
DIABETES CARE, 2005, 28 (09) :2176-2180
[5]
Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice [J].
Bennett, Brian J. ;
Scatena, Marta ;
Kirk, Elizabeth A. ;
Rattazzi, Marcello ;
Varon, Rebecca M. ;
Averill, Michelle ;
Schwartz, Stephen M. ;
Giachelli, Cecilia M. ;
Rosenfeld, Michael E. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (09) :2117-2124
[6]
Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals:: results from both cross-sectional and interventional study [J].
Gannage-Yared, Marie-Helene ;
Yaghi, Cesar ;
Habre, Bassein ;
Khalife, Simon ;
Noun, Roger ;
Germanos-Haddad, Myrna ;
Trak-Smayra, Viviane .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2008, 158 (03) :353-359
[7]
Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population [J].
Gannage-Yared, Marie-Helene ;
Fares, Florence ;
Semaan, Michelle ;
Khalife, Simon ;
Jambart, Selim .
CLINICAL ENDOCRINOLOGY, 2006, 64 (06) :652-658
[8]
Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis [J].
Gonnelli, S ;
Montagnani, A ;
Caffarelli, C ;
Cadirni, A ;
Campagna, MS ;
Franci, MB ;
Lucani, B ;
Gaggiotti, E ;
Nuti, R .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2005, 28 (06) :534-539
[9]
Emerging risk factors for atherosclerotic vascular disease - A critical review of the evidence [J].
Hackam, DG ;
Anand, SS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (07) :932-940
[10]
Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose [J].
Hofso, Dag ;
Ueland, Thor ;
Hager, Helle ;
Jenssen, Trond ;
Bollerslev, Jens ;
Godang, Kristin ;
Aukrust, Pal ;
Roislien, Jo ;
Hjelmesaeth, Joran .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2009, 161 (03) :451-458